Connect your AI

Altimmune ALT Other Financing

Other Financing at other companies

Eli LillyLLY

-$591M+13.8%

PTC TherapeuticsPTCT

$6.34M+39.4%

Esperion TherapeuticsESPR

$61K+741%

Other financials

Income statement

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's other financing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Altimmune's other financing?: Altimmune (ALT) reported other financing of $4K in Q1 2025.
What does other financing mean?: Miscellaneous financing cash flows not classified in specific line items.